Status:
COMPLETED
Study of MRA in Patients With Rheumatoid Arthritis (RA)
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.
Eligibility Criteria
Inclusion
- Patients administered MRA more than 2 times in preceding study, MRA009JP, and evaluated the efficacy and the safety.
- Patients confirmed to have shown the safety in the preceding study.
Exclusion
- Patients with Class IV Steinbrocker functional activity at evaluation within 4 weeks before treatment with the study drug
- Patients who received any of the following treatments between the start of preceding study and the registration of this study.
- Plasma exchange therapy
- Surgical treatment (e.g., operation)
Key Trial Info
Start Date :
August 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT00144651
Start Date
August 1 2001
End Date
June 1 2009
Last Update
August 9 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.